HomeCompareRPTX vs GBDC

RPTX vs GBDC: Dividend Comparison 2026

RPTX yields 75.47% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $19.42M in total portfolio value· pulled ahead in Year 8
10 years
RPTX
RPTX
● Live price
75.47%
Share price
$2.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.35M
Annual income
$375,142.22
Full RPTX calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — RPTX vs GBDC

📍 GBDC pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPTXGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPTX + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPTX pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPTX
Annual income on $10K today (after 15% tax)
$6,415.09/yr
After 10yr DRIP, annual income (after tax)
$318,870.89/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,612,003.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPTX + GBDC for your $10,000?

RPTX: 50%GBDC: 50%
100% GBDC50/50100% RPTX
Portfolio after 10yr
$11.06M
Annual income
$8,382,202.81/yr
Blended yield
75.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RPTX right now

RPTX
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$3.00
+13.2% upside vs current
Range: $3.00 — $3.00
Altman Z
-0.1
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPTX buys
0
GBDC buys
0
No recent congressional trades found for RPTX or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPTXGBDC
Forward yield75.47%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$1.35M$20.78M
Annual income after 10y$375,142.22$16,389,263.41
Total dividends collected$1.17M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$3.00$14.00

Year-by-year: RPTX vs GBDC ($10,000, DRIP)

YearRPTX PortfolioRPTX Income/yrGBDC PortfolioGBDC Income/yrGap
1$18,247$7,547.17$12,490$1,790.28+$5.8KRPTX
2$32,395$12,870.51$16,522$3,157.73+$15.9KRPTX
3$56,017$21,354.74$23,578$5,898.68+$32.4KRPTX
4$94,449$34,510.84$37,115$11,886.75+$57.3KRPTX
5$155,442$54,381.15$66,136$26,423.57+$89.3KRPTX
6$249,967$83,643.80$137,257$66,491.44+$112.7KRPTX
7$393,173$125,708.24$341,734$194,868.54+$51.4KRPTX
8← crossover$605,486$184,791.09$1,050,788$685,133.02$445.3KGBDC
9$913,831$265,960.98$4,099,314$2,974,971.01$3.19MGBDC
10$1,352,941$375,142.22$20,775,530$16,389,263.41$19.42MGBDC

RPTX vs GBDC: Complete Analysis 2026

RPTXStock

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Full RPTX Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this RPTX vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPTX vs SCHDRPTX vs JEPIRPTX vs ORPTX vs KORPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.